2017 American Society of Clinical Oncology Annual Meeting*

Adjuvant gefitinib for up to 2 years achieved superior DFS vs vinorelbine/cisplatin with no cases of interstitial lung disease.

Nivolumab with or without ipilimumab associated with durable responses in patients with advanced, previously treated SCLC.

Patients with high PD-L1 who started treatment with first-line pembrolizumab achieved better survival outcomes than those starting with first-line chemotherapy.

Patients who remained on atezolizumab after progression of disease by RECIST continued to derive benefit.

Osimertinib associated with significantly improved CNS disease control vs platinum/pemetrexed in patients with CNS metastases from advanced NSCLC.

One half of patients with irAE-related dose interruptions experienced recurrent or new irAEs during immunotherapy retreatment.

nab-Paclitaxel–based treatment was active and well tolerated in elderly patients and those with poorer ECOG performance status.

Pembrolizumab plus chemotherapy significantly improved ORR and PFS vs chemotherapy alone with comparable safety profile.

Matthew D. Hellmann, MD, and Heather Wakelee, MD, examine and discuss key lung cancer and mesothelioma presentations from the 2017 clinical oncology meeting in Chicago.

Matthew D. Hellmann, MD Heather Wakelee, MD Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: August 10, 2017 Expired: No longer available for credit

Nivolumab with and without ipilimumab was associated with 12-week disease control rates > 40% and median OS > 10 months in patients who progressed after 1-2 lines of chemotherapy.

In this phase III study, dacomitinib demonstrated superior PFS and DoR, but with increased toxicity, vs gefitinib in treatment-naive patients with advanced NSCLC and EGFR-activating mutations.

Alectinib increased median PFS more than 2-fold and delayed CNS progression with favorable toxicity compared with crizotinib.